recurrent tumor

基本解釋

Results 11C-MET was negative in 4 cases and 18F-FDG negative in 3 cases in group without remnant or recurrent tumor after operation.
結(jié)果4例腦膠質(zhì)瘤術(shù)后無腫瘤殘余或復(fù)發(fā)者11C—MET顯像為陰性，其中3例同時行18F—FDG顯像也為陰性。
Differentiating treatment induced abnormalities from residual or recurrent tumor is often difficult and requires close clinical and radiological correlation.
鑒別包括殘存或腫瘤復(fù)發(fā)導(dǎo)致的異常，通常這種鑒別是困難的，并且需要密切結(jié)合臨床及放射學(xué)改變。
This study aimed to determine the differences of prognosis between these treatments and the changes of the cytobiological characteristics between the primary and the recurrent tumor.
為了解不同消融治療方法之間的差異及治療后復(fù)發(fā)腫瘤與原發(fā)腫瘤之間細(xì)胞生物學(xué)的變化，本課題進(jìn)行了以下三個階段的研究。

腫瘤復(fù)發(fā)
Objective:Our purpose is to establish experimental animal models of postoperative scar and recurrent tumor, and to investigate in vivo proton magnetic resonance spectroscopy (1H MRS) features of the models.
目的制備術(shù)后瘢痕組織和腫瘤復(fù)發(fā)的模型,研究術(shù)后瘢痕組織和腫瘤復(fù)發(fā)的氫質(zhì)子磁共振波譜表現(xiàn)。
再發(fā)性瘤